Abstract
Faricimab is a bispecific antibody targeting ANG-2 and VEGF for the treatment of diabetic macular edema (DME). In the YOSEMITE and RHINE trials, patients treated with faricimab in a Treat & Extend (T&E) regime required less frequent treatments compared to Aflibercept given every eight weeks (Q8W) with non-inferior vision changes. However, clinical practice in DME in Canada is typically characterized by pro re nata (PRN) regimens as well as T&E. This research aims to assess the cost-effectiveness of faricimab vs. anti-VEGF treatments applied in such regimens.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
